>
  1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Logos Global Management LP Buys Celldex Therapeutics Inc, Repare Therapeutics Inc, BioNTech SE, Sells AbbVie Inc, Sarepta Therapeutics Inc, MyoKardia Inc

Investment company Logos Global Management LP (Current Portfolio) buys Celldex Therapeutics Inc, Repare Therapeutics Inc, BioNTech SE, Reata Pharmaceuticals Inc, Arena Pharmaceuticals Inc, sells AbbVie Inc, Sarepta Therapeutics Inc, MyoKardia Inc, Moderna Inc, Ascendis Pharma A/S during the 3-months ended 2020Q2, according to the most recent filings of the investment company, Logos Global Management LP. As of 2020Q2, Logos Global Management LP owns 40 stocks with a total value of $375 million. These are the details of the buys and sells.

For the details of Logos Global Management LP's stock buys and sells, go to https://www.gurufocus.com/guru/logos+global+management+lp/current-portfolio/portfolio

These are the top 5 holdings of Logos Global Management LP
  1. Reata Pharmaceuticals Inc (RETA) - 200,000 shares, 8.31% of the total portfolio. Shares added by 143.04%
  2. Celldex Therapeutics Inc (CLDX) - 2,000,000 shares, 6.93% of the total portfolio. New Position
  3. Repare Therapeutics Inc (RPTX) - 666,894 shares, 5.41% of the total portfolio. New Position
  4. BioNTech SE (BNTX) - 295,000 shares, 5.24% of the total portfolio. New Position
  5. Cytokinetics Inc (CYTK) - 800,000 shares, 5.02% of the total portfolio. Shares added by 314.23%
New Purchase: Celldex Therapeutics Inc (CLDX)

Logos Global Management LP initiated holding in Celldex Therapeutics Inc. The purchase prices were between $1.61 and $13.41, with an estimated average price of $4.32. The stock is now traded at around $12.23. The impact to a portfolio due to this purchase was 6.93%. The holding were 2,000,000 shares as of .

New Purchase: Repare Therapeutics Inc (RPTX)

Logos Global Management LP initiated holding in Repare Therapeutics Inc. The purchase prices were between $30.8 and $32.99, with an estimated average price of $32.1. The stock is now traded at around $32.67. The impact to a portfolio due to this purchase was 5.41%. The holding were 666,894 shares as of .

New Purchase: BioNTech SE (BNTX)

Logos Global Management LP initiated holding in BioNTech SE. The purchase prices were between $38.58 and $66.74, with an estimated average price of $50.01. The stock is now traded at around $63.83. The impact to a portfolio due to this purchase was 5.24%. The holding were 295,000 shares as of .

New Purchase: Arena Pharmaceuticals Inc (ARNA)

Logos Global Management LP initiated holding in Arena Pharmaceuticals Inc. The purchase prices were between $40.75 and $68.59, with an estimated average price of $54.77. The stock is now traded at around $72.75. The impact to a portfolio due to this purchase was 4.5%. The holding were 268,500 shares as of .

New Purchase: Akebia Therapeutics Inc (AKBA)

Logos Global Management LP initiated holding in Akebia Therapeutics Inc. The purchase prices were between $6.67 and $13.58, with an estimated average price of $10.28. The stock is now traded at around $2.54. The impact to a portfolio due to this purchase was 4.34%. The holding were 1,200,000 shares as of .

New Purchase: BioXcel Therapeutics Inc (BTAI)

Logos Global Management LP initiated holding in BioXcel Therapeutics Inc. The purchase prices were between $17.62 and $58.71, with an estimated average price of $40.34. The stock is now traded at around $42.05. The impact to a portfolio due to this purchase was 4.24%. The holding were 300,000 shares as of .

Added: Reata Pharmaceuticals Inc (RETA)

Logos Global Management LP added to a holding in Reata Pharmaceuticals Inc by 143.04%. The purchase prices were between $126.3 and $176.56, with an estimated average price of $151.86. The stock is now traded at around $108.61. The impact to a portfolio due to this purchase was 4.89%. The holding were 200,000 shares as of .

Added: Cytokinetics Inc (CYTK)

Logos Global Management LP added to a holding in Cytokinetics Inc by 314.23%. The purchase prices were between $11.15 and $24.64, with an estimated average price of $18.62. The stock is now traded at around $21.07. The impact to a portfolio due to this purchase was 3.81%. The holding were 800,000 shares as of .

Added: TG Therapeutics Inc (TGTX)

Logos Global Management LP added to a holding in TG Therapeutics Inc by 240.21%. The purchase prices were between $8.9 and $21.84, with an estimated average price of $16.01. The stock is now traded at around $24.72. The impact to a portfolio due to this purchase was 3.11%. The holding were 850,000 shares as of .

Added: Zogenix Inc (ZGNX)

Logos Global Management LP added to a holding in Zogenix Inc by 162.91%. The purchase prices were between $22.26 and $32.04, with an estimated average price of $27.52. The stock is now traded at around $18.68. The impact to a portfolio due to this purchase was 1.78%. The holding were 400,000 shares as of .

Added: Rocket Pharmaceuticals Inc (RCKT)

Logos Global Management LP added to a holding in Rocket Pharmaceuticals Inc by 848.83%. The purchase prices were between $13.32 and $22.61, with an estimated average price of $17.96. The stock is now traded at around $22.81. The impact to a portfolio due to this purchase was 0.75%. The holding were 150,000 shares as of .

Sold Out: AbbVie Inc (ABBV)

Logos Global Management LP sold out a holding in AbbVie Inc. The sale prices were between $73.37 and $98.18, with an estimated average price of $87.8.

Sold Out: Sarepta Therapeutics Inc (SRPT)

Logos Global Management LP sold out a holding in Sarepta Therapeutics Inc. The sale prices were between $93 and $171.7, with an estimated average price of $135.31.

Sold Out: MyoKardia Inc (MYOK)

Logos Global Management LP sold out a holding in MyoKardia Inc. The sale prices were between $44.2 and $121.69, with an estimated average price of $82.77.

Sold Out: Moderna Inc (MRNA)

Logos Global Management LP sold out a holding in Moderna Inc. The sale prices were between $29.67 and $80, with an estimated average price of $54.26.

Sold Out: Ascendis Pharma A/S (ASND)

Logos Global Management LP sold out a holding in Ascendis Pharma A/S. The sale prices were between $110.87 and $156.01, with an estimated average price of $136.82.

Sold Out: Bristol-Myers Squibb Company (BMY)

Logos Global Management LP sold out a holding in Bristol-Myers Squibb Company. The sale prices were between $54.82 and $64.09, with an estimated average price of $59.75.

Reduced: Global Blood Therapeutics Inc (GBT)

Logos Global Management LP reduced to a holding in Global Blood Therapeutics Inc by 27.39%. The sale prices were between $48.73 and $81.82, with an estimated average price of $68.29. The stock is now traded at around $53.72. The impact to a portfolio due to this sale was -1.16%. Logos Global Management LP still held 135,000 shares as of .



Here is the complete portfolio of Logos Global Management LP. Also check out:

1. Logos Global Management LP's Undervalued Stocks
2. Logos Global Management LP's Top Growth Companies, and
3. Logos Global Management LP's High Yield stocks
4. Stocks that Logos Global Management LP keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
wigbertHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)